of patients 39  Sex (male/female) [n (%)] 21/18 (53 8/46 2)  Age

of patients 39  Sex (male/female) [n (%)] 21/18 (53.8/46.2)  Age (years) [mean ± SD] 65.7 ± 10.3  Height (cm) [mean ± SD] 159.81 ± 9.61  Weight (kg) [mean ± SD] 61.952 ± 14.565  Subjects with

angina symptoms [n (%)] 37 (94.9)  Heart rate (beats/min) [mean ± SD] 77.1 ± 9.8  Systolic blood pressure (mmHg) [mean ± SD] 128.7 ± 15.3  Diastolic blood pressure (mmHg) [mean ± SD] 71.1 ± 9.6  SpO2 (%) [mean ± SD] 97.3 ± 2.2  Concomitant use with oral β-blocker 3 (7.7) CCTA conditions learn more  CT equipment [n (%)]   Siemens (16-slice) 16 (41.0)   GE (16-slice) 14 (35.9)   Toshiba (16-slice) 9 (23.1)  Time from completion of study drug administration to initiation of imaging (s) [mean ± SD] 315.7 ± 59.5  Scanning time (s) [mean ± SD] 21.7 ± 4.3  Number of subjects by administration speed of contrast medium [n (%)]   <3.5 mL/s 28 (73.7)   3.5–4.0 mL/s 9 (23.7)   >4.0 mL/s 1 (2.6)   No data 1  Total dose of contrast medium and saline (mL) [mean ± SD] 120.4 ± 10.8 CCTA coronary computed tomography angiography, CT computed tomography,

SD standard deviation, SpO 2 percutaneous oxygen saturation 3.2 Heart Rate Evaluation As shown in Table 3, heart rate at CCTA was 65.4 ± 8.0 beats/min, which was significantly lower than the value of 77.1 ± 9.8 beats/min before administration of the study drug (paired t test: p < 0.0001). The heart rate-lowering rate, defined as percent change from the baseline to SBE-��-CD clinical trial CCTA, was −14.46 ± 8.4 % and the reduction rate showed statistical significance (paired t test: p < 0.0001) as did the mean heart rate at CTTA. The heart rate then rapidly recovered toward the baseline value at approximately

6 min after completion of the study drug administration (Fig. 3). Table 3 Changes of heart rate and blood pressure at coronary computed tomography angiography selleck screening library Parameter Evaluation time point Value Heart rate (beats/min) Before administration 77.1 ± 9.8 At CCTA 65.4 ± 8.0 Change rate (%) −14.46 ± 8.4 Systolic blood pressure (mmHg) Before administration 128.7 ± 15.3 Thalidomide At CCTA 130 ± 21.1 Change rate (%) 0.41 ± 8.12 Data are given as mean ± standard deviation CCTA coronary computed tomography angiography Fig. 3 Mean ± standard deviation changes in heart rate. Rotation speed of the X-ray tube was set at the maximum speed for each type of computed tomography equipment. CCTA coronary computed tomography angiography, CT computed tomography 3.3 Blood Pressure Evaluation As shown in Fig. 4, mean systolic blood pressure was not significantly lower than the value of 128.7 ± 15.3 mmHg before administration of the study drug (paired t test: p = 0.6254). Fig. 4 Mean ± standard deviation change in blood pressure. CCTA coronary computed tomography angiography, CT computed tomography, DBP diastolic blood pressure, SBP systolic blood pressure 3.4 Percutaneous Oxygen Saturation Evaluation Mean SpO2 at 30 min after administration of the study drug was 97.9 ± 2.

Comments are closed.